Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
Conditions: Breast Cancer; Hyperinsulinism; HER2-negative Breast Cancer Intervention: Drug: Dapagliflozin 10mg Sponsors: Yale University; AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer | Cancer & Oncology | Dapagliflozin | Forxiga | HER2 | Neoadjuvant Therapy | Research | Study